Paradromics is building a high data-rate brain computer interface (BCI) to provide technology solutions for people with neurological and brain-related conditions.
Genemod is a unified platform for life scientists to collaborate and streamline day-to-day operations in the research lab. The company's proprietary technology brings together both scientific and management tools onto a single, shared platform for the multitude of tools required by scientists. They host scientific tools on a user-friendly admin dashboard and utilize data processing algorithms to streamline workflow alongside project management. It is intuitive, scalable, user-centered, modern, and secure. It was founded in 2018 and is headquartered in Seattle, Washington, USA.
Mojo Vision is focused on developing and commercializing high-performance micro-LED display technology for consumer, enterprise, and government applications. The company combines breakthrough technology, leading display and semiconductor expertise, and an advanced 300mm manufacturing process to deliver on the promise of micro-LED displays. Mojo’s proprietary quantum-dot technology brings full-color capability to its display platform and meets the superior performance demands for all form factors. Mojo Vision developed the world’s smallest, densest dynamic display for the first AR smart contact lens and is now applying this innovation and expertise to lead the disruption of the $160 billion display industry. Mojo Vision was founded in 2015 and headquartered in Saratoga, California.
Cerevance is a biotechnology company that develops novel therapeutics for neurological diseases, including chronic neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Using a large and growing repository of over 15,000 human brain tissue samples, the company generates an unprecedented level of expression and epigenetic data, enabling the company to identify the most promising targets for the next generation of treatments for CNS disorders.
Canaery is building a neural interface for analyzing an object’s scent fingerprint to identify dangerous compounds at places like ports and inspection points without (or in addition to) x-rays or cameras.
OKAPI:Orbits is a SaaS startup dedicated to making space travel more sustainable through Collision Avoidance Software for satellites.
Ubotica is to deploy advanced Artificial Intelligence technologies on board every satellite.
DigiLens is an innovator in holographic waveguide display technology for extended reality (XR).DigiLens has developed a patented optical platform and photopolymer technology that delivers best-in-class solutions using a unique, low-cost contact-copy manufacturing process. DigiLens enables OEM partners to design and build XR-enabled devices for the global automobile, enterprise, consumer, avionics, and military industries.
Diamond Age is automating new home construction for the production housing industry. Our Robotics-as-a-Service system combines 3D printing, mechatronics, and robotics to unlock the industry's enormous growth potential by backfilling the massive labor shortage and driving construction cycle times down from 9 months to 30 days.
Mojo Vision is focused on developing and commercializing high-performance micro-LED display technology for consumer, enterprise, and government applications. The company combines breakthrough technology, leading display and semiconductor expertise, and an advanced 300mm manufacturing process to deliver on the promise of micro-LED displays. Mojo’s proprietary quantum-dot technology brings full-color capability to its display platform and meets the superior performance demands for all form factors. Mojo Vision developed the world’s smallest, densest dynamic display for the first AR smart contact lens and is now applying this innovation and expertise to lead the disruption of the $160 billion display industry. Mojo Vision was founded in 2015 and headquartered in Saratoga, California.
MindImmune Therapeutics is a pharmaceutical company developing first-in-class drugs that target the immune system to treat diseases of the central nervous system, including Alzheimer’s and Huntington’s disease, pain, and psychiatric disorders. It is increasingly clear that the central nervous system and the immune system are intimately integrated. Consequently, immune system dysfunction is a critical, often causative, factor in brain dysfunction. MindImmune scientists are at the forefront in recognizing the therapeutic opportunities in targeting the immune system to treat brain disease. MindImmune is based in Kingston, RI and is building an affiliation with the George & Anne Ryan Institute for Neuroscience at the University of Rhode Island to leverage the rapidly expanding Rhode Island ecosystem of academic neurosciences resources to advance its drug development programs.
Ursa Major Technologies develops innovative propulsion solutions for the emerging microsatellite and nanosatellite launch market. Its advanced manufacturing optimizes unique part creation. These engines are greater than 80% additively manufactured by mass using innovative, internally-developed materials and processes. The company was founded in 2015 and is based in Berthoud, Colorado.
Sepion is an advanced membrane company offering a platform suite of highly-tunable nanoscale membranes for multiple industrial markets. The company was founded in 2015 and is based in Emeryville, California, United States.
Cala Health is a bioelectronic medicine company focused on developing wearable neuromodulation therapies for chronic diseases. The company integrates neuroscience and technology to provide individualized peripheral nerve stimulation. Its primary product, Cala Trio therapy, is a non-invasive prescription treatment for essential tremor. Cala Health is also working on therapies for Parkinson's disease and other neurological conditions and areas in psychiatry, cardiology, and autoimmune disorders.
DigiLens is an innovator in holographic waveguide display technology for extended reality (XR).DigiLens has developed a patented optical platform and photopolymer technology that delivers best-in-class solutions using a unique, low-cost contact-copy manufacturing process. DigiLens enables OEM partners to design and build XR-enabled devices for the global automobile, enterprise, consumer, avionics, and military industries.
Calicat is a clean-energy company developing a proprietary electrocatalyst discovery process for electrolyser. The company electrocatalyst discovery is an unprecedented, proprietary, end-to-end ultrahigh throughput AI and data-driven process focused on the discovery of new catalysts for the generation of clean hydrogen and fuel cell power production. The process prepares, characterizes, and quantifies the catalytic activity of millions of compositions per month and then closes the loop with big data analysis and AI to refine/guide the search.
TripleBlind has created the most complete and scalable solution for privacy enhancing computation. The TripleBlind solution is software-only and delivered via a simple API. It solves for a broad range of use cases, with current focus on healthcare and financial services. The company is backed by Accenture, General Catalyst and The Mayo Clinic. TripleBlind’s innovations build on well understood principles, such as federated learning and multi-party compute. Our innovations radically improve the practical use of privacy preserving technology, by adding true scalability and faster processing, with support for all data and algorithm types. TripleBlind natively supports major cloud platforms, including availability for download and purchase via cloud marketplaces. TripleBlind unlocks the intellectual property value of data, while preserving privacy and ensuring compliance with HIPAA and GDPR. TripleBlind compares favorably with other privacy preserving technologies, such as homomorphic encryption, synthetic data, and tokenization and has documented use cases for more than two dozen mission critical business problems.
Acrigen Biosciences is dedicated to making gene editing safe. It develops technologies to improve efficiency and enhance the safety of CRISPR-Cas based gene editing. CRISPR-Cas system which enables the precise enzymatic editing of genes is one of the most exciting and promising techniques to be developed in the last few years with the capability to prevent or cure many devastating diseases. It was founded in 2019 and is headquartered in Berkeley, California.
Diamond Age is automating new home construction for the production housing industry. Our Robotics-as-a-Service system combines 3D printing, mechatronics, and robotics to unlock the industry's enormous growth potential by backfilling the massive labor shortage and driving construction cycle times down from 9 months to 30 days.
Paradromics is building a high data-rate brain computer interface (BCI) to provide technology solutions for people with neurological and brain-related conditions.
Strateos operates a robotic cloud laboratory that automates chemistry, biology, and tissue analysis to enhance drug discovery processes. By integrating advanced robotics, control systems, and sophisticated imaging and analytics software, Strateos allows pharmaceutical companies to discover new drug candidates more efficiently. The company emerged from a merger between Transcriptic, known for its pioneering robotic cloud laboratory platform, and 3Scan, which specialized in using automation and machine learning to analyze tissue samples. This combination enables Strateos to provide a comprehensive suite of technologies designed to streamline the drug discovery and early development phases. By transforming life science methodologies into data-driven processes, Strateos aims to create a more efficient and cost-effective approach to scientific research, positioning itself as a valuable partner to biotechnology firms seeking to innovate in the field.
Therini Bio is a biotechnology company specializing in fibrin-targeting therapies to treat inflammatory neurological and retinal diseases. It develops therapeutics based on unique insights into the novel role of fibrin in driving chronic innate immune activation that characterizes a broad set of human diseases with high unmet needs. The current therapeutic target is based on novel findings by the Akassoglou lab at Gladstone/UCSF that implicate fibrin as a key driver of neuroinflammation.
TripleBlind has created the most complete and scalable solution for privacy enhancing computation. The TripleBlind solution is software-only and delivered via a simple API. It solves for a broad range of use cases, with current focus on healthcare and financial services. The company is backed by Accenture, General Catalyst and The Mayo Clinic. TripleBlind’s innovations build on well understood principles, such as federated learning and multi-party compute. Our innovations radically improve the practical use of privacy preserving technology, by adding true scalability and faster processing, with support for all data and algorithm types. TripleBlind natively supports major cloud platforms, including availability for download and purchase via cloud marketplaces. TripleBlind unlocks the intellectual property value of data, while preserving privacy and ensuring compliance with HIPAA and GDPR. TripleBlind compares favorably with other privacy preserving technologies, such as homomorphic encryption, synthetic data, and tokenization and has documented use cases for more than two dozen mission critical business problems.
Roviero is an AI startup that delivers graph processors for all edge computing. CortiOneTM NPE (Neural Processing Engine) and CortiSoftTM compiler technology have been developed. They created its IP and software stack to provide unrivaled performance while consuming minimal power and latency on edge devices. The Native Graph AI Processor democratizes AI compute by enabling native intelligence in edge devices such as cameras, IoT devices, mobile phones, and computers. The Roviero Native Graph AI Processor, unlike other edge AI processors, provides industry disruptive performance, power optimization, and simplified programming for product designers, enabling a new generation of edge-based intelligent devices.
CytoVale is a medical technology company that focuses on advancing early detection technologies to diagnose immune-mediated diseases, revolutionizing diagnostics using cell mechanics and machine learning. The company was founded in 2013 by Ajay Shah and Dino Di Carlo and is based in San Francisco, California.
Sea Machines Robotics develops autonomous control systems for commercial vessels. The technology enables navigation in marine environments. The focus is on applications in sectors such as shipping, offshore energy, and maritime logistics.
Authentic Vision is best known for providing new and innovative ways of brand protection. The company holds several patents and is cooperating closely with universities and the world’s leading security printing companies to stay abreast of the latest developments in the fields of brand/value protection and costumer communication solutions.
Libra Therapeutics, Inc. operates as a biotechnology company that develops novel disease-modifying therapeutics and drug candidates for restoring the cellular balance disrupted in neurodegenerative diseases. The company’s therapeutic platform discovers and develops small molecule drugs to attenuate the production of neurotoxic proteins for the treatment of amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's disease. The company was founded in 2019 and is based in San Diego, California.
Salvia is an innovative startup active in the emerging field of bioelectronics. The name Salvia is derived from the Latin word salvere, which means to stay healthy. In addition, the Salvia-plant has been used to treat headaches, pain, and mental disorders over centuries. Salvia's mission is to deliver bioelectronic solutions that restore health for people suffering from chronic migraine. Salvia aims to provide drug-free solutions that are effective and inherently side-effect free and make the novel solutions widely accessible. The Salvia team consists of experienced entrepreneurs, engineers and scientists with diverse professional backgrounds and proven track-record throughout the medical device industry (Sapiens, Medtronic, Philips, St Jude, BioSensors International, Kyphon, etc).
NeuroTherpia develop new therapies for diseases with an underlying component of neuroinflammation. Initial research has led to the development of our lead compound NTRX-07. NTRX-07 (previously known as MDA7) has been shown to decrease activation of microglial cells in the brain. Decreasing activation of these cells leads to decreased inflammation and decreased injury to surrounding nerve cells. Decreasing this inflammation can treat and even prevent the development of neuropathic pain in settings of nerve injury or chemotherapy. Recent work has shown that blocking this inflammation is also important in reversing the effects seen in Alzheimer's disease. We are currently doing preclinical safety studies and plan on studying NTRX-07 in humans in 2016.
NativeWaves' vision is to provide the ultimate event watching experience for everyone worldwide. NativeWaves works with partners to identify the most compelling content from live events and creates tools that enables them to deliver the best-in-class personalised viewing experiences to their viewers, using intuitive and easy-to-use technology solutions. Efficient, Versatile, Agile and Non-Disruptive content delivery solutions, with no changes to existing workflows.
Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster. Learn more at atomwise.com, or connect on Twitter and LinkedIn.
QurAlis is a clinical-stage biotechnology company that is developing precision medicines with genetically validated targets for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Its proprietary platforms and biomarkers allow for the design and development of drugs that target disease-causing genetic alterations directly.
Cerevance is a biotechnology company that develops novel therapeutics for neurological diseases, including chronic neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Using a large and growing repository of over 15,000 human brain tissue samples, the company generates an unprecedented level of expression and epigenetic data, enabling the company to identify the most promising targets for the next generation of treatments for CNS disorders.
EnClear Therapies is a Cambridge (USA) based life sciences company developing a device-based therapy to aid in the treatment of neurodegenerative disease and delivery and monitoring of cerebrospinal fluid (CSF). EnClear’s proprietary therapeutic platform focuses on removing toxic proteins from the CSF. The company’s first products will target improving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP).
Atmosic Technologies is a fabless semiconductor business that develops ultra-low power wireless technologies to provide perpetual battery life and the connected Internet of Things that are battery-free. The company's technology enables devices to source power from ambient energy like light, radio frequency, thermal, and kinetic sources. The company's product lineup, including the ATM2, ATM3, ATM33, and ATM34 series, supports various IoT applications such as wearables, remotes, beacons, sensors, and asset tracking.
GenomSys is a Swiss health software company accelerating personalized genomics. As genomic applications are becoming widespread and data volumes are growing, there is a pressing need for data and process efficiency, interoperability, and software robustness. GenomSys offer a unique multi-infrastructure genomic platform, based on the ISO/IEC 23092 genomic standard (MPEG-G, "the MP3 for genomic data") we contributed to shape, enabling fast time-to-market of innovative applications with high potential. GenomSys solutions are cheaper (storage needs -70%), faster (4-month time-to-market of innovative application), interoperable, ready for mobile personal genomics, regulatory conscious.
Strateos operates a robotic cloud laboratory that automates chemistry, biology, and tissue analysis to enhance drug discovery processes. By integrating advanced robotics, control systems, and sophisticated imaging and analytics software, Strateos allows pharmaceutical companies to discover new drug candidates more efficiently. The company emerged from a merger between Transcriptic, known for its pioneering robotic cloud laboratory platform, and 3Scan, which specialized in using automation and machine learning to analyze tissue samples. This combination enables Strateos to provide a comprehensive suite of technologies designed to streamline the drug discovery and early development phases. By transforming life science methodologies into data-driven processes, Strateos aims to create a more efficient and cost-effective approach to scientific research, positioning itself as a valuable partner to biotechnology firms seeking to innovate in the field.
Therini Bio is a biotechnology company specializing in fibrin-targeting therapies to treat inflammatory neurological and retinal diseases. It develops therapeutics based on unique insights into the novel role of fibrin in driving chronic innate immune activation that characterizes a broad set of human diseases with high unmet needs. The current therapeutic target is based on novel findings by the Akassoglou lab at Gladstone/UCSF that implicate fibrin as a key driver of neuroinflammation.
Lightform provides sound-reactive projectors, projector kits, and creator products. Their products transform spaces using projection mapping, adding effects and ambient interfaces to any 3D object. They design hardware tools for projection. Their user interface streamlined the projection mapping workflow and pairing process.
NativeWaves' vision is to provide the ultimate event watching experience for everyone worldwide. NativeWaves works with partners to identify the most compelling content from live events and creates tools that enables them to deliver the best-in-class personalised viewing experiences to their viewers, using intuitive and easy-to-use technology solutions. Efficient, Versatile, Agile and Non-Disruptive content delivery solutions, with no changes to existing workflows.
Kuprion’s™ revolutionary, copper based nanotechnology is a highly electrically conductive material enabling a new generation of printable electronics and integrated circuit chips. Connections between chip-to-chip or chip-to-board are up to 10 times the electrical and thermal conductivity of existing materials - perfect for smaller and more powerful products from phones to electric cars. Our nanoCopper technology is based on work that began at Lockheed Martin in 2008. They were researching ways to replace traditional solder with a high-performance, RoHS- compliant alternative for high-power, high-reliability applications. With widespread interest from the commercial sector, all rights and patents were transferred to Kuprion in 2019 to commercialize the family of pastes and inks. Since then, Kuprion has garnered Fortune 100 customers, 20 patents, and VC funding with offices and manufacturing in San Jose, CA
Phylagen, Inc. is a data analytics company leveraging artificial intelligence to harness the vast, unseen world of microbes. Phylagen uses DNA sequencing and machine learning to turn the largest untapped dataset on the planet, the environmental microbiome, into insights for customers across numerous industries.
Ultraleap is the world leader in mid-air haptics and 3D hand tracking. The company's breakthrough haptic technology (previously Ultrahaptics) uses ultrasound to create rich, three-dimensional shapes and textures that can be felt, but not seen.
Mojo Vision is focused on developing and commercializing high-performance micro-LED display technology for consumer, enterprise, and government applications. The company combines breakthrough technology, leading display and semiconductor expertise, and an advanced 300mm manufacturing process to deliver on the promise of micro-LED displays. Mojo’s proprietary quantum-dot technology brings full-color capability to its display platform and meets the superior performance demands for all form factors. Mojo Vision developed the world’s smallest, densest dynamic display for the first AR smart contact lens and is now applying this innovation and expertise to lead the disruption of the $160 billion display industry. Mojo Vision was founded in 2015 and headquartered in Saratoga, California.
System1 Biosciences, Inc., is a San Francisco-based neurotherapeutics company that employs phenotypic screening to discover novel drugs for complex neurological and psychiatric diseases such as epilepsy, autism, and schizophrenia, disorders for which current discovery techniques have proved least successful. System1 combines cerebral organoid science, systems neuroscience, robotic automation, and advanced data analytics to discover characterizations of disease never before achievable. These “deep phenotypes” are exploited to identify novel therapeutic targets and drug treatments.
Vium is a biotechnology company that develops digital biomarkers to transform preclinical research and animal welfare. It is fully accredited by AAALAC International and received an unprecedented AAALAC commendation for upholding the 3 Rs, the gold-standard framework for humane animal research. Customers run the spectrum of biotechnology, pharmaceutical, and computational drug discovery companies to academia and novel therapeutic labs. Vium's digital platform provides physiological biomarkers that enable better decisions on which compounds should be advanced to the clinic. The company's platform Digital Vivariumand Vium Cloud is the gold-standard in vivo platform combining computer vision, artificial intelligence, machine learning, and sensor technology to non-invasively collect and derive insights from digital biomarkers. The platform continuously captures physiological metrics and behaviors non-invasively, providing more sensitive and accurate data collection, leading to more replicable studies. Vium was founded in 2013 and is headquartered in San Mateo, California, United States.
Paradromics is building a high data-rate brain computer interface (BCI) to provide technology solutions for people with neurological and brain-related conditions.
Zebra Medical Vision’s imaging analytics platform allows healthcare institutions to identify patients at risk of disease and offer improved preventative treatment pathways to advance patient care. The company is funded by Khosla Ventures, Marc Benioff, Intermountain Investment Fund, OurCrowd Qure, Aurum, aMoon, Nvidia, J&J, and Dolby Ventures. Zebra Medical Vision has raised $52 million in funding to date and was named a Fast Company Top-5 AI and Machine Learning company. Zebra-Med leads the way in AI FDA cleared products, and is installed in hospitals globally, from Australia to India, Europe to the U.S, and the LATAM region.
Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.
Phase Four is a provider of electric propulsion (EP) for small satellites. The company was founded in 2015 to accelerate the advancement of its core differentiator, the Radio Frequency Thruster (RFT). The hallmark of Phase Four’s RFT is simplicity. Because the RFT omits a hollow cathode and high voltage electronics, three key improvements are realized: 1) a 10x materials cost savings versus legacy EP systems, 2) a significant decrease in the size of power electronics, and 3) propellant agnosticism. In a first for EP, the Phase Four RF thruster accomplishes this while achieving performance in the same thrust, specific impulse (Isp), and efficiency class as legacy plasma propulsion solutions.
Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster. Learn more at atomwise.com, or connect on Twitter and LinkedIn.
Envisagenics focus on the discovery of RNA therapeutics. Their mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused by mutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be discovered. Their breakthrough technology, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery from RNA-seq data, using Artificial Intelligence. We are using our software to identify splicing errors causative of diseases, identify the right drug targets, and develop RNA therapeutics through partnerships and collaborations with Biopharma. Their in-silico RNA therapeutics discovery platform replaces expensive drug-target selection and lead design with efficient computer simulations, decreasing time, cost, and failure risk of drug development programs. Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory.
Ursa Major Technologies develops innovative propulsion solutions for the emerging microsatellite and nanosatellite launch market. Its advanced manufacturing optimizes unique part creation. These engines are greater than 80% additively manufactured by mass using innovative, internally-developed materials and processes. The company was founded in 2015 and is based in Berthoud, Colorado.
Lightform provides sound-reactive projectors, projector kits, and creator products. Their products transform spaces using projection mapping, adding effects and ambient interfaces to any 3D object. They design hardware tools for projection. Their user interface streamlined the projection mapping workflow and pairing process.
Athira Pharma is a clinical-stage drug development company striving to improve human health by advancing bold and innovative therapies with the potential to restore the lives of people impacted by brain disorders. Athira is derived from the word Athir, the energy that reaches everyone. It captures its mission to develop therapies that can reach and positively impact everyone.
Stellar is an advanced commercial operations system created for private aviation combined with an all-digital distribution network. Stellar is reimagining and revolutionizing the business aviation industry with a suite of integrated, cloud-based applications. Its solution is simple enough for single-aircraft operations, yet comprehensive and robust enough to handle the most complex operations with large fleets and multiple bases. It was founded in 2014 and is headquartered in Burlingame, California.
Founded in 2013, Chirp Microsystems, Inc. designs, develops, and manufactures a line of extremely low power, ultrasonic 3D-sensing solutions for consumer electronics, smart homes, industrial automation, and much more. Located in downtown Berkeley near the UC campus.
Mixed Dimensions is an integral reality company, creating new systems and technologies for the virtual and physical worlds to relate to one another by bridging the digital and physical worlds through an innovative software platform. Its manufacturing innovative technology enables on demand, no inventory, processing of one of a kind objects realized through leading edge 3D printing, robotics, and artists delivering products that bring the imagination from the virtual world to life for use in our physical world.
Alzeca Biosciences develops novel advanced imaging agents for the early diagnosis of neurodegenerative diseases, including Alzheimer’s Disease. Alzheimer’s affects approximately 5.5M Americans at a cost of over $226 billion in care, and affects over 27 million patients worldwide. Its incidence is projected to quadruple by 2050 with costs exceeding $1 trillion in the US alone, unless a more effective diagnostic and treatment method is achieved.
Tempo Automation is transforming the way companies innovate and bring new electronic products to market. Tempo’s breakthrough, software-automated PCBA manufacturing platform delivers unprecedented speed, quality and transparency at the most critical time in a product’s lifecycle – prototype through new product introduction – when fast iteration and time to market are imperatives. Customers who count on Tempo Automation for this strategic advantage include the leading innovators in aerospace, medical technology, semiconductor, industrial technology, automotive and other key industries.
Ultraleap is the world leader in mid-air haptics and 3D hand tracking. The company's breakthrough haptic technology (previously Ultrahaptics) uses ultrasound to create rich, three-dimensional shapes and textures that can be felt, but not seen.
Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.
Athira Pharma is a clinical-stage drug development company striving to improve human health by advancing bold and innovative therapies with the potential to restore the lives of people impacted by brain disorders. Athira is derived from the word Athir, the energy that reaches everyone. It captures its mission to develop therapies that can reach and positively impact everyone.
Echo is a provider of am automated microscope intended for biological research and pathologies. The company's product provides features like inverted images, cell counting, phase contrast, brightfield and fluorescence, enabling customers to have accurate images at a lower cost.
DigiLens is an innovator in holographic waveguide display technology for extended reality (XR).DigiLens has developed a patented optical platform and photopolymer technology that delivers best-in-class solutions using a unique, low-cost contact-copy manufacturing process. DigiLens enables OEM partners to design and build XR-enabled devices for the global automobile, enterprise, consumer, avionics, and military industries.
Tetra Therapeutics is a clinical stage biotechnology company developing a portfolio of therapeutic products that will bring clarity of thought to people suffering from Fragile X syndrome, Alzheimer's disease, traumatic brain injury, and other brain disorders.
Podium Data uses big data technologies to redefine the enterprise data management. Podium dramatically accelerates time-to-answer with a secure, self-service platform that delivers immediate business impact.
3Scan is turning tissue into bits by building robotic microscopy tools and software for large-scale sample analysis and 3D visualizations. Many diseases emerge only at a tissue level, such as cancer, heart disease, lung disease, stroke, Alzheimer's, and diabetes. 3Scan enables higher throughput, greater quantification, and broader image analysis than what is currently possible with traditional histopathology. 3Scan's data-driven approach is expanding our understanding of tissue biology and will lead to the discovery of new diagnostics and therapeutics. The company was founded in 2011 and is headquartered in San Francisco, California.
Zebra Medical Vision’s imaging analytics platform allows healthcare institutions to identify patients at risk of disease and offer improved preventative treatment pathways to advance patient care. The company is funded by Khosla Ventures, Marc Benioff, Intermountain Investment Fund, OurCrowd Qure, Aurum, aMoon, Nvidia, J&J, and Dolby Ventures. Zebra Medical Vision has raised $52 million in funding to date and was named a Fast Company Top-5 AI and Machine Learning company. Zebra-Med leads the way in AI FDA cleared products, and is installed in hospitals globally, from Australia to India, Europe to the U.S, and the LATAM region.
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Founded in December 2014 by award-winning protein folding expert, Susan Lindquist, and renowned biotech industry leader, Tony Coles, Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The initial focus of the company is neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). The company’s proprietary platforms have already identified one potential new target for treating Parkinson’s disease, and Yumanity is actively advancing its new chemical lead series for this condition, as well as identifying additional compounds for Alzheimer’s disease and ALS.
Athira Pharma is a clinical-stage drug development company striving to improve human health by advancing bold and innovative therapies with the potential to restore the lives of people impacted by brain disorders. Athira is derived from the word Athir, the energy that reaches everyone. It captures its mission to develop therapies that can reach and positively impact everyone.
Modsy combines advanced 3D graphics, computer vision, and creative curation to provide its customers with home design guidance and plans. It allows its customers to see inspirational designs and decor within the context of their own home and shows ideas for their space before making any changes. Modsy helps new homeowners, remodelers, and renters create an ideal, personalized design. It was founded in 2015 and is headquartered in San Francisco, California.
Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.
Eargo specializes in the design and development of hearing aids. The company also offers online hearing screenings and virtual support, so customers don’t need to have an in-person visit. It offers rechargeable hearing aids that can be controlled with a smartphone. Its innovative product and go-to-market approach address the challenges of traditional hearing aid adoption, including social stigma, accessibility, and cost.
San Francisco's PharmatrophiX, a biotech working on drugs that prevent neurodegenerative disease. Founded by Stanford researcher Frank Longo, PharmatrophiX is developing a class of drugs that mimic the activity of proteins called neurotrophins, which aid in the development, health and survival of neurons.
Stellar is an advanced commercial operations system created for private aviation combined with an all-digital distribution network. Stellar is reimagining and revolutionizing the business aviation industry with a suite of integrated, cloud-based applications. Its solution is simple enough for single-aircraft operations, yet comprehensive and robust enough to handle the most complex operations with large fleets and multiple bases. It was founded in 2014 and is headquartered in Burlingame, California.
What if you could rethink human communication? What if you could perceive, peruse, and process information in milliseconds? What if you could accelerate intelligence at the speed of sight? At Eyefluence, we are engineering the ability to transform intent into action through your eyes. Leveraging eye biomechanics and the eye-brain connection with the first-ever eye-interaction technology solution for HMDs, we are expanding human potential and creating new possibility in VR, AR, and MR worlds. Eyefluence is a multidisciplinary team of world-class experts in UX design, optics, electrical engineering, mechanical engineering, physics, math, computer vision, computer science, artificial intelligence, and machine learning. Led by successful serial entrepreneurs Jim Marggraff and David Stiehr, we are united by a passion for creating the best possible experiences in VR, AR, and MR realms. We are dedicated to solving the most complex technical challenges related to true eye-interaction for HMDs. Eyefluence’s technology is based on an IP portfolio with more than 30 patents granted or pending. We are engaged in development with emerging startups and Fortune 100 companies that are working to accelerate the wide adoption of smart glasses, including AR, VR and MR headsets, for enterprise, industrial, government, and consumer applications.
Cognition Therapeutics, Inc. is focused on the discovery and development of small molecule therapeutics targeting the toxic proteins that cause the cognitive decline associated with Alzheimer's disease and other degenerative diseases of the human brain. Toxic proteins play a crucial role in a large class of disease targets, and there are currently no therapeutics available to prevent toxic protein accumulation or block their destructive effects. Cognition is founded on the unique combination of biological expertise around these targets, including proprietary assays that emphasize functional responses and proprietary medicinal chemistry that insures novel, high quality small-molecule drug candidates.
AltspaceVR is a virtual reality software company. AltspaceVR is bringing two-dimensional web content into shared virtual spaces, and extending the web to create fully holographic experiences. Through the software users will be able to watch streaming video, play games, and get work done, together and entirely inside of virtual reality. The software is powered by, and fully embraces, the modern open web.
Cognition Therapeutics, Inc. is focused on the discovery and development of small molecule therapeutics targeting the toxic proteins that cause the cognitive decline associated with Alzheimer's disease and other degenerative diseases of the human brain. Toxic proteins play a crucial role in a large class of disease targets, and there are currently no therapeutics available to prevent toxic protein accumulation or block their destructive effects. Cognition is founded on the unique combination of biological expertise around these targets, including proprietary assays that emphasize functional responses and proprietary medicinal chemistry that insures novel, high quality small-molecule drug candidates.
ZOZI designs and develops a web-based bookings, payments, and customer management software for tour, activity, and event businesses. It offers introductory flight lessons, vineyard tours and wine tasting by horseback, diving for abalone, ice climbing frozen waterfalls, celebrity and athlete experiences, and various accessible adventures. The company also provides weekend getaways and vacation packages for customers. ZOZI was founded in 2007 and is based in San Francisco, California.
Eargo specializes in the design and development of hearing aids. The company also offers online hearing screenings and virtual support, so customers don’t need to have an in-person visit. It offers rechargeable hearing aids that can be controlled with a smartphone. Its innovative product and go-to-market approach address the challenges of traditional hearing aid adoption, including social stigma, accessibility, and cost.
Vium is a biotechnology company that develops digital biomarkers to transform preclinical research and animal welfare. It is fully accredited by AAALAC International and received an unprecedented AAALAC commendation for upholding the 3 Rs, the gold-standard framework for humane animal research. Customers run the spectrum of biotechnology, pharmaceutical, and computational drug discovery companies to academia and novel therapeutic labs. Vium's digital platform provides physiological biomarkers that enable better decisions on which compounds should be advanced to the clinic. The company's platform Digital Vivariumand Vium Cloud is the gold-standard in vivo platform combining computer vision, artificial intelligence, machine learning, and sensor technology to non-invasively collect and derive insights from digital biomarkers. The platform continuously captures physiological metrics and behaviors non-invasively, providing more sensitive and accurate data collection, leading to more replicable studies. Vium was founded in 2013 and is headquartered in San Mateo, California, United States.
Mixed Dimensions is an integral reality company, creating new systems and technologies for the virtual and physical worlds to relate to one another by bridging the digital and physical worlds through an innovative software platform. Its manufacturing innovative technology enables on demand, no inventory, processing of one of a kind objects realized through leading edge 3D printing, robotics, and artists delivering products that bring the imagination from the virtual world to life for use in our physical world.
New Matter was founded in 2014 with a mission to bring 3D printing to every home, school, and office. Led by its flagship product, the MOD-t desktop 3D printer, New Matter is poised to revolutionize the consumer 3D printing market by providing the first and only affordable, fully integrated, end-to-end consumer 3D printing experience.
GoBalto is a software platform that develops cloud-based solutions for drug trial sponsors and clinical research organizations. Its products offer drug trial sponsors and clinical research organizations the fastest, easiest possible way to start clinical studies on the web. The company was founded in 2008 and headquartered in San Francisco, California.
3Scan is turning tissue into bits by building robotic microscopy tools and software for large-scale sample analysis and 3D visualizations. Many diseases emerge only at a tissue level, such as cancer, heart disease, lung disease, stroke, Alzheimer's, and diabetes. 3Scan enables higher throughput, greater quantification, and broader image analysis than what is currently possible with traditional histopathology. 3Scan's data-driven approach is expanding our understanding of tissue biology and will lead to the discovery of new diagnostics and therapeutics. The company was founded in 2011 and is headquartered in San Francisco, California.
Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.
Keyssa reinvented the connector with Kiss Connectivity. It’s a tiny solid-state system that makes device-to-device data flow simple, secure and instantaneous - freeing product designers and consumers from metal connectors, cables and wireless networks. Kiss Connectivity is a new way to transmit huge amounts of data and video rapidly between devices in close proximity, with virtually no battery drain. Keyssa’s coffee bean-sized connector combines breakthroughs in mechanical design, electromagnetics, materials science, and semiconductor technologies. Because this tiny system uses extremely high frequency (EHF) signals to transmit information securely using standard protocols, it avoids the manufacturing and consumer challenges of today’s other wired or wireless-network options for connecting devices.
Authentic Vision is best known for providing new and innovative ways of brand protection. The company holds several patents and is cooperating closely with universities and the world’s leading security printing companies to stay abreast of the latest developments in the fields of brand/value protection and costumer communication solutions.
Wickr is a free top-secret messaging app allowing its users to send and receive top-secret messages, pictures, videos, audios, and files. Its aim is to provide a free and easy way for anyone to send encrypted messages without a trace. Both sender and receiver must have the app to communicate. Only the receiver is able to decrypt the message once it was sent, and Wickr does not have the decryption keys. Wickr has hundreds of thousands of downloads in over 113 countries. Its clients include celebrities, royalty, reporters, feds, lawyers, doctors, investors, and teens. Its patent-pending technology brings sophisticated security and privacy to everybody. Wickr’s protocol for ephemeral messaging and media uses standard encryption algorithms implemented for mobile devices. This protocol can be integrated into other communications platforms, creating a unified mobile messaging platform that is private, encrypted, and anonymous. Wickr was launched in 2011 and is based in San Francisco, California. It supports the 1st Amendment of the United States.
CytoVale is a medical technology company that focuses on advancing early detection technologies to diagnose immune-mediated diseases, revolutionizing diagnostics using cell mechanics and machine learning. The company was founded in 2013 by Ajay Shah and Dino Di Carlo and is based in San Francisco, California.
August Pro, a division of August Home, specializes in providing smart home access solutions tailored for professional installers. Founded in 2012 and headquartered in San Francisco, California, August Home develops advanced smart home products, including the flagship August Smart Lock, which replaces traditional keys with smartphone-controlled access. This technology allows users to create virtual keys for their homes, granting temporary access to house cleaners, dog walkers, delivery services, and others, all managed through a mobile app. The company's products are designed to enhance home security and convenience, enabling homeowners to monitor and control access from anywhere in the world. August Home operates as a subsidiary of ASSA ABLOY AB, further strengthening its position in the smart home market.
At Basis our mission is to help fit health into our busy lives. We designed our wrist-based health tracker and online personal dashboard to help you easily incorporate healthy habits into your daily routine. Basis leverages four types of advanced sensors in its lightweight, customizable design to calculate steps taken, calories burned and sleep quality, as well as physiological metrics like heart rate. We help you set new health goals and automatically adjust weekly targets based on your progress. Using this flexible approach you’ll build healthy habits you can maintain for years. Basis Science, Inc. is backed by Norwest Venture Partners and Doll Capital Management.
Littlecast is a peer-to-peer e-commerce platform for video producers and their audiences. It provides direct-to-fan monetization of videos. The platform offers iOS and Android applications, content protection support, analytics on fans and viewers, Facebook social integration, payment processing, quick producer payouts, and many other services. Littlecast was launched in 2013 and is based in San Francisco, California.
Tetra Discovery Partners provides consulting services in drug discovery and development. They partner with Universities to commercialize intellectual property and conduct proprietary research on diseases affecting the central nervous system. Their research focuses on developing new treatments for depression and schizophrenia. Severe forms of depression affect 2–5% of the US population, while mood disorders impact 7% of the world’s population and rank among the top ten causes of disability.
ICON Aircraft’s mission is to accelerate the democratization of personal flight and 3-D mobility. ICON creates consumer-friendly, safe, technologically advanced aircraft that make the adventure of flying more accessible to mainstream consumers. ICON’s first aircraft is the A5, an amphibious sport plane that fuses outstanding aeronautical engineering with world-class product design and unprecedented safety features. The A5 is the world’s first production aircraft that is spin-resistant, making it arguably one of the safest small aircraft ever created. The A5 has won some of the world’s most prestigious design awards and has inspired a global following. The company culture is defined by an entrepreneurial, fast-paced, performance-driven meritocracy where intelligent risk-taking is encouraged and the organizational structure is flat and collaborative. ICON seeks A-players who are a strong cultural fit and driven to change the world by creating truly innovative products.
ZOZI designs and develops a web-based bookings, payments, and customer management software for tour, activity, and event businesses. It offers introductory flight lessons, vineyard tours and wine tasting by horseback, diving for abalone, ice climbing frozen waterfalls, celebrity and athlete experiences, and various accessible adventures. The company also provides weekend getaways and vacation packages for customers. ZOZI was founded in 2007 and is based in San Francisco, California.